Cosomil, Inc. established on April 1, 2022. Cosomil, Inc. is an academia-launched start-up aiming for social implementation of disease diagnosis by utilizing “Single-molecule Enzyme Activity-based Liquid Biopsy”. This combines the “fluorescent detection of enzyme activity” technology of Assistant Professor Toru Komatsu at the Graduate School of Pharmaceutical Sciences of the University of Tokyo and the “single molecule measurement” technology of Rikiya Watanabe, a RIKEN Senior Scientist.

Our company was established after R&D and business development under the New Industry Creation Program for Academia (START) of the Japan Science and Technology Agency (JST) from November 2020 to March 2022 (research title: Commercialization of Single Molecule Liquid Biopsy, PI: Toru Komatsu, Assistant Professor, Graduate School of Pharmaceutical Sciences, The University of Tokyo, business promoter: ANRI Inc. Ltd.). Moreover, our company has been certified as a RIKEN Venture, a start-up support program of RIKEN.

<About our company>

Company name: Cosomil, Inc.

Location: 5-25-18 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

Date of establishment: April 1, 2022

Capital ：2 million yen

Representative ：Yu Kagami

＜What is JST START?>

JST START is a competitive research grant from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) to support the commercialization of high-potential technology seeds by combining public funds for R&D and business development with private-sector commercialization know-how from the pre-startup stage.

＜What is RIKEN Venture?>

RIKEN Venture is a group of companies established primarily for the purpose of implementing the results of RIKEN’s research into society, which have been certified by RIKEN as having the ability to quickly commercialize the core technology of their research results and making meaningful use.